BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014;20:518-25. [PMID: 24370861 DOI: 10.1016/j.bbmt.2013.12.565] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Kolev M, Barbour T, Baver S, Francois C, Deschatelets P. With complements: C3 inhibition in the clinic. Immunol Rev 2022. [PMID: 36161656 DOI: 10.1111/imr.13138] [Reference Citation Analysis]
2 Denson A, Croom Taylor M, Arnall J. Considerations for the Role of the Pharmacist in Managing Patients on Eculizumab for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Ann Pharmacother 2022;:10600280221123089. [PMID: 36062453 DOI: 10.1177/10600280221123089] [Reference Citation Analysis]
3 Qi J, Pan T, You T, Tang Y, Chu T, Chen J, Fan Y, Hu S, Yang F, Ruan C, Wu D, Han Y. Upregulation of HIF-1α contributes to complement activation in transplantation-associated thrombotic microangiopathy. Br J Haematol 2022. [PMID: 35864790 DOI: 10.1111/bjh.18377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Reference Citation Analysis]
5 Meri S, Bunjes D, Cofiell R, Jodele S. The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Adv Ther 2022. [PMID: 35781192 DOI: 10.1007/s12325-022-02184-4] [Reference Citation Analysis]
6 Marini I, Uzun G, Jamal K, Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica 2022;107:1264-77. [PMID: 35642486 DOI: 10.3324/haematol.2021.279484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica 2022;107:1243-63. [PMID: 35642485 DOI: 10.3324/haematol.2021.279512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med 2022;11:623. [PMID: 35160072 DOI: 10.3390/jcm11030623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Weiss SL, Carcillo JA, Leclerc F, Leteurtre S, Schlapbach LJ, Tissieres P, Wynn JL, Lacroix J. Refining the Pediatric Multiple Organ Dysfunction Syndrome. Pediatrics 2022;149:S13-22. [PMID: 34970671 DOI: 10.1542/peds.2021-052888C] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Qi J, Hu S, He X, Pan T, Yang L, Zhang R, Tang Y, Wu D, Han Y. N-Acetyl-L-Cysteine Potentially Inhibits Complement Activation in Transplantation-Associated Thrombotic Microangiopathy. Transplant Cell Ther 2021:S2666-6367(21)01451-2. [PMID: 34979328 DOI: 10.1016/j.jtct.2021.12.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Stenson EK, You Z, Reeder R, Norris J, Scott HF, Dixon BP, Thurman JM, Frazer-Abel A, Mourani P, Kendrick J. Complement Activation Fragments Are Increased in Critically Ill Pediatric Patients with Severe AKI. Kidney360 2021;2:1884-91. [PMID: 35419539 DOI: 10.34067/KID.0004542021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Gomez-Ganda L, Benitez-Carabante MI, Fernandez-Polo A, Muñoz-Lopez M, Renedo-Miro B, Ariceta G, Diaz De Heredia C. Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy. Front Pediatr 2021;9:761726. [PMID: 34858907 DOI: 10.3389/fped.2021.761726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Gavriilaki E, Sakellari I, Chatzikonstantinou T, Bousiou Z, Mallouri D, Masmanidou M, Vardi A, Koravou EE, Kika F, Touloumenidou T, Papalexandri A, Yannaki E, Batsis I, Anagnostopoulos A. Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease. Transplant Proc 2021;53:2261-6. [PMID: 34417030 DOI: 10.1016/j.transproceed.2021.07.043] [Reference Citation Analysis]
15 Tamburro RF, Cooke KR, Davies SM, Goldfarb S, Hagood JS, Srinivasan A, Steiner ME, Stokes D, DiFronzo N, El-Kassar N, Shelburne N, Natarajan A; Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation Workshop Participants. Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. Ann Am Thorac Soc 2021;18:381-94. [PMID: 33058742 DOI: 10.1513/AnnalsATS.202001-006OT] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yang LP, Liu X, Zhang XH. [Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:693-9. [PMID: 34547882 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood 2021;137:1310-7. [PMID: 33512445 DOI: 10.1182/blood.2019003810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:177-84. [PMID: 33910301 DOI: 10.3760/cma.j.issn.0253-2727.2021.03.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, Battersby A, Flood T, Owens S, Cant AJ, Young H, Greener S, Walsh P, Kavanagh D, Annavarapu S, Rao K, Amrolia P, Chiesa R, Worth A, Booth C, Skinner R, Doncheva B, Standing J, Gennery AR, Qasim W, Slatter M, Veys P. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv 2020;4:2418-29. [PMID: 32492158 DOI: 10.1182/bloodadvances.2019001315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
20 Schoettler M, Lehmann LE, Margossian S, Lee M, Kean LS, Kao PC, Ma C, Duncan CN. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv 2020;4:2536-47. [PMID: 32516415 DOI: 10.1182/bloodadvances.2019001242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-17. [PMID: 33875812 DOI: 10.1038/s41409-021-01283-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
22 Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol 2021;14:101081. [PMID: 33862523 DOI: 10.1016/j.tranon.2021.101081] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
23 Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, Sharma S, Cai Y, Ingraham S, Winnicki E, Weaver DJ, Hunley TE, Kiessling SG, Seamon M, Woroniecki R, Miyashita Y, Xiao N, Omoloja AA, Kizilbash SJ, Mansuri A, Kallash M, Yu Y, Sherman AK, Srivastava T, Nester CM. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021;36:2349-60. [PMID: 33693990 DOI: 10.1007/s00467-021-04965-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:564647. [PMID: 33552043 DOI: 10.3389/fimmu.2020.564647] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
25 Kanunnikov MM, Rakhmanova ZZ, Levkovsky NV, Vafina AI, Goloshapov OV, Shchegoleva TS, Vlasova JJ, Paina OV, Morozova EV, S Zubarovskaya L, Kulagin AD, S Moiseev I. Conversion from calcineurin inhibitors to sirolimus in transplant-associated thrombotic microangiopathy. Clin Transplant 2021;35:e14180. [PMID: 33258122 DOI: 10.1111/ctr.14180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, Chase J, Liebling EJ, Burudpakdee C, Lee JH, Balamuth FB, Blatz AM, Chiotos K, Fitzgerald JC, Giglia TM, Gollomp K, Odom John AR, Jasen C, Leng T, Petrosa W, Vella LA, Witmer C, Sullivan KE, Laskin BL, Hensley SE, Bassiri H, Behrens EM, Teachey DT. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv 2020;4:6051-63. [PMID: 33290544 DOI: 10.1182/bloodadvances.2020003471] [Cited by in Crossref: 29] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
27 Nada A, Jetton JG. Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy. Pediatr Nephrol 2021;36:2227-55. [PMID: 33245421 DOI: 10.1007/s00467-020-04800-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mezö B, Horváth O, Sinkovits G, Veszeli N, Kriván G, Prohászka Z. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation. Front Med (Lausanne) 2020;7:569291. [PMID: 33117830 DOI: 10.3389/fmed.2020.569291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jarmoliński T, Rosa M, Puziewicz-Zmonarska A, Kałwak K. Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report. Transplant Proc 2020;52:2544-7. [PMID: 32917392 DOI: 10.1016/j.transproceed.2020.08.040] [Reference Citation Analysis]
31 Han Y. [How I treat transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2020;41:272-5. [PMID: 32447928 DOI: 10.3760/cma.j.issn.0253-2727.2020.04.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
32 Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019;58:859-74. [PMID: 30758736 DOI: 10.1007/s40262-019-00742-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 53] [Article Influence: 19.0] [Reference Citation Analysis]
33 Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, Peffault de Latour R, Socie G. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv 2019;3:2424-35. [PMID: 31409584 DOI: 10.1182/bloodadvances.2019000143] [Cited by in Crossref: 23] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
34 Bray MA, Sartain SE, Gollamudi J, Rumbaut RE. Microvascular thrombosis: experimental and clinical implications. Transl Res 2020;225:105-30. [PMID: 32454092 DOI: 10.1016/j.trsl.2020.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
35 Guo QX, Zhang MY, Wang JG, Zhou F, Liu YQ, Liu JH. [Pulmonary arterial hypertension caused by graft-related thrombotic microangiopathy after ETP-ALL haplotype hematopoietic stem cell transplantation: a case report and literatures review]. Zhonghua Xue Ye Xue Za Zhi 2020;41:164-6. [PMID: 32135636 DOI: 10.3760/cma.j.issn.0253-2727.2020.02.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Wanchoo R, Stotter BR, Bayer RL, Jhaveri KD. Acute kidney injury in hematopoietic stem cell transplantation. Curr Opin Crit Care 2019;25:531-8. [PMID: 31524721 DOI: 10.1097/MCC.0000000000000657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
37 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
38 Saida K, Fukuda T, Mizuno K, Ogura M, Kamei K, Ito S. Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Front Pediatr 2019;7:519. [PMID: 31921730 DOI: 10.3389/fped.2019.00519] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH. Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clin J Am Soc Nephrol 2020;15:289-97. [PMID: 31836598 DOI: 10.2215/CJN.08580719] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
40 Sartain S, Shubert S, Wu M, Wang T, Martinez C. The alternative complement pathway activation product Ba as a marker for transplant‐associated thrombotic microangiopathy. Pediatr Blood Cancer 2019;67. [DOI: 10.1002/pbc.28070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
41 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 432] [Article Influence: 104.7] [Reference Citation Analysis]
42 Tolbert VP, Dvorak CC, Golden C, Vissa M, El-haj N, Perwad F, Matthay KK, Vo KT. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biology of Blood and Marrow Transplantation 2019;25:2031-9. [DOI: 10.1016/j.bbmt.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
43 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
44 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
45 Fernández-zarzoso M, Gómez-seguí I, de la Rubia J. Therapeutic plasma exchange: Review of current indications. Transfusion and Apheresis Science 2019;58:247-53. [DOI: 10.1016/j.transci.2019.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
46 Le Clech A, Simon-tillaux N, Provôt F, Delmas Y, Vieira-martins P, Limou S, Halimi J, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-chiche N, Rondeau E, Frémeaux-bacchi V, Fakhouri F. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International 2019;95:1443-52. [DOI: 10.1016/j.kint.2019.01.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
47 Palomo M, Diaz-Ricart M, Carreras E. Endothelial Dysfunction in Hematopoietic Cell Transplantation. Clin Hematol Int 2019;1:45-51. [PMID: 34595410 DOI: 10.2991/chi.d.190317.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
48 Schoettler M, Duncan C, Lehmann L. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab. Pediatr Transplant 2019;23:e13381. [PMID: 30828947 DOI: 10.1111/petr.13381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Schoettler M, Lehmann L, Li A, Ma C, Duncan C. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors. Biol Blood Marrow Transplant 2019;25:e163-8. [PMID: 30639820 DOI: 10.1016/j.bbmt.2018.12.840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
50 Sartain S, Shubert S, Wu M, Srivaths P, Teruya J, Krance R, Martinez C. Therapeutic Plasma Exchange does not Improve Renal Function in Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy: An Institutional Experience. Biology of Blood and Marrow Transplantation 2019;25:157-62. [DOI: 10.1016/j.bbmt.2018.08.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
51 Schuh MP, Bennett MR, Lane A, Jodele S, Laskin BL, Devarajan P. Haptoglobin degradation product as a novel serum biomarker for hematopoietic stem cell transplant-associated thrombotic microangiopathy. Pediatr Nephrol 2019;34:865-71. [PMID: 30569313 DOI: 10.1007/s00467-018-4178-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
52 Cavero T, Alonso M. Where are we with haemolytic uremic syndrome? Med Clin (Barc) 2018;151:329-35. [PMID: 29699703 DOI: 10.1016/j.medcli.2018.02.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Genere L, Bacchetta J, Bertrand Y, Javouhey E, Cheikh N, Sellier-Leclerc AL. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients. Arch Pediatr 2018;25:485-8. [PMID: 30340942 DOI: 10.1016/j.arcped.2018.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
54 Thurman JM. Complement Biomarkers of Hemolytic Uremic Syndrome-If Not One Thing, Maybe Another. Mayo Clin Proc 2018;93:1337-9. [PMID: 30286826 DOI: 10.1016/j.mayocp.2018.08.024] [Reference Citation Analysis]
55 Wanchoo R, Bayer RL, Bassil C, Jhaveri KD. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments. Am J Kidney Dis 2018;72:857-65. [PMID: 30146419 DOI: 10.1053/j.ajkd.2018.06.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
56 Gavriilaki E, Sakellari I, Batsis I, Mallouri D, Bousiou Z, Vardi A, Yannaki E, Constantinou V, Tsompanakou A, Vadikoliou C, Kaloyannidis P, Bamihas G, Anagnostopoulos A. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 2018;32:e13371. [DOI: 10.1111/ctr.13371] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
57 Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transplant 2019;54:540-8. [DOI: 10.1038/s41409-018-0293-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
58 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
59 Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol 2018;101:389-98. [PMID: 29920784 DOI: 10.1111/ejh.13127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
60 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia 2017;37:478-91. [PMID: 28946961 DOI: 10.1016/j.nefro.2017.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
61 Tomlinson S, Thurman JM. Tissue-targeted complement therapeutics. Mol Immunol 2018;102:120-8. [PMID: 30220307 DOI: 10.1016/j.molimm.2018.06.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
62 Wirtschafter E, VanBeek C, Linhares Y. Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature. Exp Hematol Oncol. 2018;7:14. [PMID: 29977661 DOI: 10.1186/s40164-018-0106-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
63 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
64 Kar S, Paglialunga S, Islam R. Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies. J Clin Pharmacol 2018;58:1239-47. [PMID: 29775220 DOI: 10.1002/jcph.1132] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
65 Jodele S, Dandoy CE, Myers K, Wallace G, Lane A, Teusink-Cross A, Weiss B, Davies SM. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Bone Marrow Transplant 2018;53:1311-8. [PMID: 29674658 DOI: 10.1038/s41409-018-0159-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
66 Raina R, Herrera N, Krishnappa V, Sethi SK, Deep A, Kao WM, Bunchman T, Abu-Arja R. Hematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review. Pediatr Transplant 2017;21. [PMID: 28485097 DOI: 10.1111/petr.12935] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
67 Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21-40. [PMID: 29447987 DOI: 10.1016/j.cmi.2018.02.002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 23.5] [Reference Citation Analysis]
68 Cupit-Link MC, Kohorst MA, Tran CL, Bleesing JJ, Galardy PJ, Boyce TG. Suspected thrombotic microangiopathy in a child with Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2018;65:e27002. [PMID: 29411928 DOI: 10.1002/pbc.27002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Horváth O, Kállay K, Csuka D, Mező B, Sinkovits G, Kassa C, Stréhn A, Csordás K, Sinkó J, Prohászka Z, Kriván G. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation. Biol Blood Marrow Transplant 2018;24:989-96. [PMID: 29339271 DOI: 10.1016/j.bbmt.2018.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
70 Weitz IC. Thrombotic microangiopathy in cancer. Thromb Res 2018;164 Suppl 1:S103-5. [PMID: 29703465 DOI: 10.1016/j.thromres.2018.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
71 Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-29. [PMID: 27257797 DOI: 10.1097/QCO.0000000000000279] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 18.5] [Reference Citation Analysis]
72 Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2017;32:466-74. [PMID: 28339660 DOI: 10.1093/ndt/gfw453] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 13.4] [Reference Citation Analysis]
73 Upperman JS, Lacroix J, Curley MA, Checchia PA, Lee DW, Cooke KR, Tamburro RF. Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1. Pediatr Crit Care Med 2017;18:S50-7. [PMID: 28248834 DOI: 10.1097/PCC.0000000000001048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
74 Upperman JS, Bucuvalas JC, Williams FN, Cairns BA, Cox CS Jr, Doctor A, Tamburro RF. Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 2. Pediatr Crit Care Med 2017;18:S58-66. [PMID: 28248835 DOI: 10.1097/PCC.0000000000001051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
75 Seaby EG, Gilbert RD. Thrombotic microangiopathy following haematopoietic stem cell transplant. Pediatr Nephrol 2018;33:1489-500. [PMID: 28993886 DOI: 10.1007/s00467-017-3803-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
76 Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant 2018;53:129-37. [DOI: 10.1038/bmt.2017.207] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
77 Laskin BL, Jodele S. Kidney Disease in Cancer Survivors: Focus on Hematopoietic Stem Cell Transplantation. Journal of Onco-Nephrology 2017;1:163-9. [DOI: 10.5301/jo-n.5000031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
79 Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, Schwarzwälder P, Döhner H, Bunjes D, Bommer M. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. Biol Blood Marrow Transplant 2017;23:2172-7. [PMID: 28860002 DOI: 10.1016/j.bbmt.2017.08.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
80 Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017;57:2775-2781. [PMID: 28836275 DOI: 10.1111/trf.14263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
81 Henry M, Valentini RP, Savaşan S. Thrombotic microangiopathy associated with monoclonal gammopathy following autologous hematopoietic stem cell transplantation for neuroblastoma in a young child. Bone Marrow Transplant 2017;52:1662-4. [PMID: 28825693 DOI: 10.1038/bmt.2017.181] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
82 Qi J, Wang J, Chen J, Su J, Tang Y, Wu X, Ma X, Chen F, Ruan C, Zheng XL, Wu D, Han Y. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Ann Hematol 2017;96:1849-55. [PMID: 28801815 DOI: 10.1007/s00277-017-3092-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
83 Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, Rao K, Lucchini G, Silva JMF, Worth A, Barge D, Ryan D, Conn J, Cant AJ, Skinner R, Abd Hamid IJ, Flood T, Abinun M, Hambleton S, Gennery AR, Veys P, Slatter M. T-cell receptor αβ+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol 2018;141:1417-1426.e1. [PMID: 28780238 DOI: 10.1016/j.jaci.2017.07.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 14.2] [Reference Citation Analysis]
84 Han W, Han Y, Chen J, Ma X, Chen F, Wu XJ, Qi JQ, Qiu HY, Sun AN, Wu DP. [Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2016;37:666-70. [PMID: 27587247 DOI: 10.3760/cma.j.issn.0253-2727.2016.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Facchini L, Lucchesi M, Stival A, Roperto RM, Melosi F, Materassi M, Farina S, Tintori V, de Martino M, Sardi I. Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report. J Med Case Rep 2017;11:209. [PMID: 28747219 DOI: 10.1186/s13256-017-1373-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
86 Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatr Nephrol 2018;33:1297-307. [DOI: 10.1007/s00467-017-3744-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
87 Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN, Lane A, Wilkey A, Lake KE, Litts B, Davies SM. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood 2017;130:1259-66. [PMID: 28705839 DOI: 10.1182/blood-2017-05-782870] [Cited by in Crossref: 44] [Cited by in F6Publishing: 53] [Article Influence: 8.8] [Reference Citation Analysis]
88 Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura JI, Nunn MA, Mackie I, Machin SJ, Palm L, Pryce JW, Chiesa R, Amrolia P, Veys P. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv 2017;1:1254-8. [PMID: 29296765 DOI: 10.1182/bloodadvances.2016002832] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
89 Hasegawa D, Saito A, Nino N, Uemura S, Takafuji S, Yokoi T, Kozaki A, Ishida T, Kawasaki K, Yasumi T, Sakata N, Ohtsuka Y, Hirase S, Mori T, Nishimura N, Kusumoto M, Ogawa Y, Tominaga K, Nakagawa T, Kanda K, Tanaka R, Kosaka Y. Successful Treatment of Transplantation-associated Atypical Hemolytic Uremic Syndrome With Eculizumab. J Pediatr Hematol Oncol 2018;40:e41-4. [PMID: 28538511 DOI: 10.1097/MPH.0000000000000862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
90 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
91 Ardissino G, Salardi S, Berra S, Colussi G, Cugno M, Zecca M, Giglio F, Peccatori J, Diral E, Tel F, Clivio A, Tedeschi S. Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy. Biol Blood Marrow Transplant 2017;23:1580-2. [PMID: 28522344 DOI: 10.1016/j.bbmt.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
92 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
93 Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol 2017;180:25-32. [PMID: 28366510 DOI: 10.1016/j.clim.2017.03.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
94 Abusin GA, Abu-Arja R, Bajwa RPS, Horwitz EM, Auletta JJ, Rangarajan HG. Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies. Pediatr Blood Cancer 2017;64. [PMID: 28333416 DOI: 10.1002/pbc.26503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
95 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 251] [Article Influence: 33.6] [Reference Citation Analysis]
96 Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora's box. Bone Marrow Transplant 2017;52:1355-60. [PMID: 28287636 DOI: 10.1038/bmt.2017.39] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
97 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 216] [Article Influence: 40.4] [Reference Citation Analysis]
98 Farkas P, Csuka D, Mikes B, Sinkovits G, Réti M, Németh E, Rácz K, Madách K, Gergely M, Demeter J, Prohászka Z. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology 2017;222:119-27. [DOI: 10.1016/j.imbio.2016.10.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
99 Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15:312-22. [PMID: 27868334 DOI: 10.1111/jth.13571] [Cited by in Crossref: 190] [Cited by in F6Publishing: 221] [Article Influence: 38.0] [Reference Citation Analysis]
100 Machida S, Onizuka M, Toyosaki M, Aoyama Y, Kawai H, Amaki J, Hara R, Ichiki A, Ogawa Y, Kawada H, Ando K. Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant 2017;52:307-9. [PMID: 27892947 DOI: 10.1038/bmt.2016.270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Sahin U, Ataca Atilla P, Atilla E, Toprak SK, Demirer T. An overview of hematopoietic stem cell transplantation related thrombotic complications. Critical Reviews in Oncology/Hematology 2016;107:149-55. [DOI: 10.1016/j.critrevonc.2016.09.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
102 Renaudon-Smith E, De La Fuente J, Bain BJ. Transplant-associated thrombotic microangiopathy. Am J Hematol 2016;91:1160. [PMID: 27348509 DOI: 10.1002/ajh.24459] [Reference Citation Analysis]
103 Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017;52:352-6. [PMID: 27775697 DOI: 10.1038/bmt.2016.253] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
104 Kemmner S, Verbeek M, Heemann U. Renal dysfunction following bone marrow transplantation. J Nephrol 2017;30:201-9. [PMID: 27589851 DOI: 10.1007/s40620-016-0345-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
105 Troxell ML, Higgins JP, Kambham N. Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. Adv Anat Pathol 2016;23:310-29. [PMID: 27403615 DOI: 10.1097/PAP.0000000000000122] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
106 Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thomé SD, Hook CC; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc 2016;91:1189-211. [PMID: 27497856 DOI: 10.1016/j.mayocp.2016.05.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
107 Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab. Clin Nephrol 2015;84:181-5. [PMID: 25816809 DOI: 10.5414/CN108532] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
108 Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb Hemost 2017;23:175-80. [DOI: 10.1177/1076029615599439] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
109 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
110 Webb J, Abraham A. Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation. Transfus Med Rev 2016;30:202-8. [PMID: 27439965 DOI: 10.1016/j.tmrv.2016.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
112 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
113 Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, Laskin BL. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54:181-190. [PMID: 27156964 DOI: 10.1016/j.transci.2016.04.007] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
114 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
115 Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 2016;51:1241-4. [PMID: 27064689 DOI: 10.1038/bmt.2016.87] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
116 Obut F, Kasinath V, Abdi R. Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant 2016;51:891-7. [DOI: 10.1038/bmt.2016.61] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
117 Pulsipher MA. Fishing for complements. Blood 2016;127:957-8. [PMID: 26917734 DOI: 10.1182/blood-2015-12-685131] [Reference Citation Analysis]
118 Fernández C, Lario A, Forés R, Cabrera R. Eculizumab Treatment in a Patient with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy and Steroid-Refractory Acute Graft Versus Host Disease. Hematol Rep 2015;7:6107. [PMID: 26734129 DOI: 10.4081/hr.2015.6107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
119 Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:307-15. [PMID: 26456258 DOI: 10.1016/j.bbmt.2015.10.002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 11.7] [Reference Citation Analysis]
120 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 12.6] [Reference Citation Analysis]
121 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
122 de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay J, Neven B, Moussi J, Simon L, Xhaard A, Resche-riggon M, O’meara A, Fremeaux-bacchi V, Veyradier A, Socié G, Coppo P, de Latour RP. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. Transplantation 2015;99:1953-9. [DOI: 10.1097/tp.0000000000000601] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 11.3] [Reference Citation Analysis]
123 Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK. Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb Hemost 2016;22:12-20. [PMID: 26239316 DOI: 10.1177/1076029615598221] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
124 El-Bietar J, Warren M, Dandoy C, Myers KC, Lane A, Wallace G, Davies SM, Jodele S. Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2015;21:1994-2001. [PMID: 26150023 DOI: 10.1016/j.bbmt.2015.06.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
125 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
126 Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015;66:857-68. [PMID: 25943718 DOI: 10.1053/j.ajkd.2015.02.340] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
127 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 257] [Article Influence: 38.9] [Reference Citation Analysis]
128 Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P. Atypical aHUS: State of the art. Mol Immunol. 2015;67:31-42. [PMID: 25843230 DOI: 10.1016/j.molimm.2015.03.246] [Cited by in Crossref: 162] [Cited by in F6Publishing: 150] [Article Influence: 23.1] [Reference Citation Analysis]
129 Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 114] [Article Influence: 15.6] [Reference Citation Analysis]
130 Sakamoto K, Imamura T, Osone S, Nishimura A, Nishida M, Ishida H, Hosoi H. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition. Pediatr Transplantation 2015;19:E97-E100. [DOI: 10.1111/petr.12450] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
131 Weitz IC. Complement the hemostatic system: an intimate relationship. Thromb Res 2014;133 Suppl 2:S117-21. [PMID: 24862131 DOI: 10.1016/S0049-3848(14)50020-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
132 Connelly-smith LS, Linenberger ML. Therapeutic Apheresis for Patients with Cancer. Cancer Control 2015;22:60-78. [DOI: 10.1177/107327481502200109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
133 Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015;29:191-204. [PMID: 25483393 DOI: 10.1016/j.blre.2014.11.001] [Cited by in Crossref: 155] [Cited by in F6Publishing: 156] [Article Influence: 19.4] [Reference Citation Analysis]
134 Contreras E, de la Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M; Grupo Español de Aféresis. [Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group]. Med Clin (Barc) 2015;144:331.e1-331.e13. [PMID: 25433791 DOI: 10.1016/j.medcli.2014.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
135 Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
136 Kim SS, Patel M, Yum K, Keyzner A. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options: Treatment Review of Thrombotic Microangiopathy. Transfusion 2015;55:452-8. [DOI: 10.1111/trf.12859] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
137 Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. [PMID: 25250305 DOI: 10.3389/fped.2014.00097] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
138 Kambham N, Higgins JP, Sundram U, Troxell ML. Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver, and lung. Adv Anat Pathol 2014;21:301-20. [PMID: 25105933 DOI: 10.1097/PAP.0000000000000032] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
139 Nester CM, Smith RJ. Factors influencing treatment of atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1516-8. [PMID: 25135763 DOI: 10.2215/CJN.07540714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014;124:645-53. [PMID: 24876561 DOI: 10.1182/blood-2014-03-564997] [Cited by in Crossref: 203] [Cited by in F6Publishing: 200] [Article Influence: 25.4] [Reference Citation Analysis]
141 Cataland SR. Eculizumab Therapy. Biology of Blood and Marrow Transplantation 2014;20:438-9. [DOI: 10.1016/j.bbmt.2014.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Lerner D, Dandoy C, Hirsch R, Laskin B, Davies SM, Jodele S. Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy. Bone Marrow Transplant 2014;49:862-3. [DOI: 10.1038/bmt.2014.40] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
143 Li WY, Li XL, He XF, Ma X, Han Y, Wu DP, Sun AN. [Thrombotic microangiopathy with lack of ADAMT13 activity after allogeneic hematopoietic stem cell transplantation: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2017;38:1072-4. [PMID: 29365405 DOI: 10.3760/cma.j.issn.0253-2727.2017.12.015] [Reference Citation Analysis]